港股異動 | 藥明生物(2269.HK)低開4.44% 大股東配股套現逾61億港元
格隆匯9月2日丨藥明生物(2269.HK)低開4.44%,報189.5港元,總市值2572億港元。藥明生物公佈,於2020年9月1日,該公司董事會獲該公司其中一名主要股東WuXi Biologics Holdings Limited(WBH)知會,其透過摩根士丹利國際以每股185港元的價格向獨立投資者配售由WBH持有的該公司3299.69萬股現有股份(相當該公司已發行股本總額約2.43%)。WBH套現逾61億港元。假設配售將按預期完成,WBH持有的該公司股權將由該公司已發行股本總額約25.77%減少至約23.35%;且WBH將繼續為該公司主要股東。昨日的銷售文件顯示,集團控股股東WBH計劃配售3300萬股,每股配售價介乎183至188港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.